We categorized CML patients into different statuses according to the level of BCR-ABL1 and TKI-treatment response: de novo CML (DN-CML: BCR-ABL1 > 10%), molecular remission (MR: BCR-ABL1 < 10%), and TKI-F. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.